Discriminative power of inflammatory markers for prediction of tumor necrosis factor-α and interleukin-6 in ICU patients with systemic inflammatory response syndrome (SIRS) or sepsis at arbitrary time points

Intensive Care Medicine, Supplement

Volumn 26, Issue 2, 2000, Pages

  Oberhoffer, M ^a   Russwurm S ^a   Bredle, D ^b   Chatzinicolaou, K ^c   Reinhart, K ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF WISCONSIN EAU CLAIRE   (United States)

^c GENERAL HOSPITAL   (Greece)

Author keywords

Body temperature; C reactive protein; Correlation; Interleukin 6; Leukocyte count; Predictive value; Procalcitonin; Receiver operating characteristic; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 6; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; CLINICAL FEATURE; FEMALE; HEMOLYTIC STREPTOCOCCUS; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PREDICTION; PROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0034103888     PISSN: 09351701     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02900732     Document Type: Article

References (31)

1. 1. Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119: 771-778
2. 2. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103: 565-575
3. 3. Barriere SL, Lowry SF (1995) An overview of mortality risk prediction in sepsis [see comments]. Crit Care Med 23: 376-393
4. 4. Waage A, Halstensen A, Espevik T (1987) Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1 (8529): 355-357
5. 5. Bone RC (1996) Why sepsis trials fail. JAMA 276: 565-566
6. 6. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group [see comments]. JAMA 266: 1097-1102
7. 7. Solomkin JS, Hill CS (1995) Design problems in clinical sepsis trials. In: Tellado JM, Forse RA, Solomkin JS (eds) Modulation of the inflammatory response in severe sepsis. Karger, Basel, pp 59-66
8. 8. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN (1991) Treatment of gram-negative bacteremia and septic shock with HA-1 A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1 A Sepsis Study Group [see comments]. N Engl J Med 324: 429-436
9. 9. Natanson C, Hoffmann WD, Suffredini A, Eichacker PQ, Danner RL (1994) Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120: 771-783
10. 10. Fisher CJ, Opal SM, Dhainaut JL (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21: 318-327
11. 11. Bone RC, Balk RA, Cerra FB (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine. Chest 101: 1644-1655
12. 12. Agresti A(1990) Categorical data analysis. Wiley, New York
13. 13. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiving operator characteristic curves derived from the same cases. Radiology 148: 839-843
14. 14. Peduzzi P, Shatney C, Sheagren J, Sprung C (1992) Predictors of bacteremia and gram-negative bacteremia in patients with sepsis. The Veterans Affairs Systemic Sepsis Cooperative Study Group. Arch Intern Med 152: 529-535
15. 15. Meisner M, Tschaikowsky K, Palmaers T, Hoefig J, Schuettler J (1996) Procalcitonin and CRP in septic shock: inflammatory parameters with different kinetics. Intensive Care Med 22:14
16. 16. Meisner M, Tschaikowsky K, Palmaers T, Prudlo U, Hoefig J, Schuettler J (1996) Procalcitonin und CRP bei Sepsis und Multiorganversagen: Korrelationen zu APACHE II und SOFA-Score? Anaesthesist 45: 170
17. 17. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C (1994) Procalcitonin increases after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79: 1605-1608
18. 18. Bohuon C, Petitjean S, Assicot M (1994) Blood procalcitonin is a new biological marker of the human septic response. New data on the specificity. Clin Intensive Care 5: 88
19. 19. Gendrel D, Raymond J, Assicot M, Moulin F, Bergeret M, Badoual J, Bohuon C (1995) Procalcitonin in bacterial and viral meningitis in children. International Congress for Antibiotics. ICAC. 20th September, 1995
20. 20. Brunkhorst F, Forycki Z, Wagner J (1995) Procalcitonin immunoreactivity in severe human shock. Intensive Care Med 21: 12
21. 21. Raue F, Blind E, Grauer A (1992) PDN-21 (katacalcin) and chromogranin A: tumor markers for medullary thyroid carcinoma. Henry Ford Hosp Med J 40: 296-298
22. 22. Bretagna XY, Nicholson WE, Pettengill OS, Sorensen GD, Mount CD, Orth DN (1978) Ectopic production of high molecular weight calcitonin and corticotropin by human small cell carcinoma cells in tissue culture: evidence for separate precursors. J Clin Endocrinol Metab 47: 1390-1393
23. 23. Gendrel D, Assicot M, Raymond J, Moulin R, Bergeret M, Francoual C, Badoual J, Bohuon C (1996) Procalcitonin as a marker for the early diagnosis of neonatal infection. J Pediatr 128: 570-573
24. 24. Brunkhorst FM, Forycki ZF, Wagner J (1995) Discrimination of infectious and non-infectious etiologies of the adult respiratory distress syndrome (ARDS) with procalcitonin immunoreactivity. Clin Intensive Care 6: 3
25. 25. Gramm HJ, Dollinger P, Beier W (1995) Procalcitonin - ein neuer Marker der inflammatorischen Wirtsantwort. Longitudinalstudien bei Patienten mit Sepsis und Peritonitis. Chir Gastroenterol 11: 51-54
26. 26. Oberhoffer M, Boegel D, Meier-Hellmann A, Vogelsang H, Reinhart K (1996) Procalcitonin vs immunological markers in infection/inflammation. Br J Anaesth 76: A352
27. 27. Oberhoffer M, Bitterlich A, Hentschel T, Meier-Hellmann A, Vogelsang H, Reinhart K (1996) Procalcitonin (ProCt) correlates better with the ACCP/SCCM Consensus Conference definitions than other specific markers of the inflammatory response. Clin Intensive Care 7: 46
28. 28. De Werra I, Jaccard C, Corradin SB, Chiolero R, Yersin B, Gallati H, Assicot M, Bohuon C, Baumgartner JD, Glauser MP, Heumann (1997) Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock and bacterial pneumonia. Crit Care Med 25: 607-613
29. 29. Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent JL (1999) Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 27: 498-504
30. 30. Darville T, Girior B, Jacobs R (1993) The systemic inflammatory response syndrome (SIRS): immunology and potential immunotherapy. Infection 21: 279-290
31. 31. Oberhoffer M, Karzai W, Meier-Hellmann A, Bögel D, Faßbinder J, Reinhart K (1999) Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-α and interleukin-6 in patients with sepsis. Crit Care Med 27: 1814-1818